A promising adjuvant chemotherapeutic regimen for resected pancreatic cancer?

WOS: 000387080500019PubMed ID: 2778290

Early combined immunosupression for the management of Crohn's disease

WOS: 000382747100022PubMed ID: 2745886

Long-term effects of a flexible sigmoidoscopy screening after 17 years of follow up

WOS: 000411468300022PubMed ID: 2893697

Eicosapentaenoic acid and aspirin for colorectal adenomas

WOS: 000462165900017PubMed ID: 3084386

Practice patterns and considerations in liver transplantation from living donors with high BMI: A review

Living Donor Liver Transplantation (LDLT) is a valuable solution to the shortage of donor organs for patients with end-stage liver disease. However, the eligibility of obese donors for LDLT remains a subject of debate. This literature review explores global practices and perceptions of LDLT, identifies donor eligibility criteria, and discusses special considerations and ethical caveats. The review highlights the need for standardized guidelines for donor selection, considering the global distribution of Body mass index and variations in population-specific criteria. It also emphasizes the importance of non-invasive testing and pre-operative optimization of liver steatosis for select obese donors. Furthermore, the review examines the outcomes and complications associated with obese donors in LDLT. The findings of this review contribute to the ongoing discussion on the inclusion of obese donors in LDLT and provide insights for future research and guideline development

An unusual cause of anaemia: Rapunzel syndrome, a case report

Trichobezoars present with stomach ache and with a mass in the stomach. It's common in the young and middle-aged women having psychiatric disorder, presenting with stomach ache and existence of mass in the stomach. Although it's one of the rare causes of anaemia it should be considered when dealing with cases of chronic and unresponsive anaemia

Real-life experience of ledipasvir and sofosbuvir single-tablet regimen among chronic hepatitis C patients in Turkey

WOS: 000529401300006PubMed: 32343236Background/Aims: Ledipasvir (LDV) and sofosbuvir (SOF) as single-tablet regimen (STR) has been approved for treatment of chronic HCV infection (CHC) for treatment-naive or experienced cirrhotic or non-cirrhotic patients. Our aim was to analyse the effectiveness and safety of 12-24 weeks treatment of LDV/SOF (90mg/400 mg)+/- ribavirin in a real-life setting in Turkey. Materials and Methods: Between May-Dec 2016, 104 treatment-naive or experienced adult patients with CHC and with or without cirrhosis (including decompensated cirrhosis) were included in this observational study. Patients were administered LDV/SOF STR +/- ribavirin once daily for 12-24 weeks. SVR12 rates and effects of the baseline characteristics on SVR12 rates were assessed. Results: Out of 104 enrolled patients (61.5% female, mean age 62.0 years); 60.6% were cirrhotic, 76.0% previously used peg-IFN, 94.2% had GT1. At the end of the treatment, 77.8% (77/99, no data for 21 patients) had undetectable HCV-RNA and 98.9% (94/95) had SVR12. in the baseline characteristics subgroups, the SVR12 rates varied between 94.4% and 100%, and none of the baseline characteristics had a significant effect on the SVR12 rates. During the study, 6 (5.8%) patients died and none of the deaths was suspected to be related to the LDV/SOF. No treatment-emergent adverse event was reported. Conclusion: in conclusion, LDV/SOF +/- ribavirin yielded very high SVR12 rates, without any safety or tolerability concern in Turkey. the effectiveness of the LDV/SOF treatment was not affected by the patient demographics or medical characteristics such as fibrosis level, cirrhosis status, previous treatment status, HCV-RNA level or HCV genotype.Gilead Sciences, TurkeyGilead SciencesThis study was supported by Gilead Sciences, Turkey for editorial support in the preparation of this manuscript

The Efficacy of Paritaprevir/Ritonavir/Ombitasvir/Dasabuvir with or without Ribavirin in Patients with Hepatitis C Undergoing Chronic Haemodialysis: A Single Center Experience

Objectives: Paritaprevir/Ritonavir/Ombitasvir/Dasabuvir (PrOD) seems to be highly effective and safe in chronic haemodialysis (CHD) patients. We presented our experiences of treatment with PrOD in CHD patients